MX2009012271A - Compuestos antagonistas de acido ribonucleico para la modulacion de her3. - Google Patents
Compuestos antagonistas de acido ribonucleico para la modulacion de her3.Info
- Publication number
- MX2009012271A MX2009012271A MX2009012271A MX2009012271A MX2009012271A MX 2009012271 A MX2009012271 A MX 2009012271A MX 2009012271 A MX2009012271 A MX 2009012271A MX 2009012271 A MX2009012271 A MX 2009012271A MX 2009012271 A MX2009012271 A MX 2009012271A
- Authority
- MX
- Mexico
- Prior art keywords
- her3
- her2
- oligomers
- egfr
- modulation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91739207P | 2007-05-11 | 2007-05-11 | |
| US2325008P | 2008-01-24 | 2008-01-24 | |
| PCT/EP2008/055779 WO2008138904A2 (en) | 2007-05-11 | 2008-05-09 | Rna antagonist compounds for the modulation of her3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012271A true MX2009012271A (es) | 2010-02-04 |
Family
ID=40002684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012271A MX2009012271A (es) | 2007-05-11 | 2008-05-09 | Compuestos antagonistas de acido ribonucleico para la modulacion de her3. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8268793B2 (enExample) |
| EP (1) | EP2155877A2 (enExample) |
| JP (1) | JP2010526797A (enExample) |
| KR (1) | KR20100024410A (enExample) |
| CN (1) | CN101849007A (enExample) |
| AU (1) | AU2008250033A1 (enExample) |
| BR (1) | BRPI0811156A2 (enExample) |
| CA (1) | CA2686908A1 (enExample) |
| EA (1) | EA200971049A1 (enExample) |
| IL (1) | IL202038A0 (enExample) |
| MX (1) | MX2009012271A (enExample) |
| NZ (1) | NZ581201A (enExample) |
| TW (1) | TW200908987A (enExample) |
| WO (1) | WO2008138904A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| NZ581201A (en) | 2007-05-11 | 2012-05-25 | Enzon Pharmaceuticals Inc | Rna antagonist compounds for the modulation of her3 |
| KR20110086844A (ko) * | 2008-11-07 | 2011-08-01 | 엔즌 파마슈티칼스, 인코포레이티드 | Ｅｒｂｂ－３（ｈｅｒ３）－선택적 조합 요법 |
| AR076053A1 (es) * | 2009-04-14 | 2011-05-18 | Schering Corp | Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor |
| US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| AU2012229147B2 (en) | 2011-03-11 | 2015-12-24 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers |
| US20150231238A1 (en) | 2011-03-15 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
| AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| EP3511416A1 (en) | 2012-05-16 | 2019-07-17 | Translate Bio MA, Inc. | Compositions and methods for modulating gene expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| JP6492053B2 (ja) | 2013-03-27 | 2019-03-27 | イサルナ セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾ｔｇｆ−ベータオリゴヌクレオチド |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| EP3271460A4 (en) | 2015-03-17 | 2019-03-13 | The General Hospital Corporation | RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1) |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CN116492365A (zh) * | 2022-01-19 | 2023-07-28 | 圣诺生物医药技术(广州)有限公司 | 抑制HER2和HER3的siRNA药物组合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| WO1999034016A2 (en) * | 1997-12-29 | 1999-07-08 | Genena Ltd. | A method for identifying and characterizing cells and tissues |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| US6277640B1 (en) | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| US20050176024A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
| BRPI0313202A8 (pt) * | 2002-08-05 | 2016-08-16 | Atugen Ag | Formas adicionais para interferir com as moléculas de rna |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
| WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| EP2141234B1 (en) * | 2003-03-21 | 2016-04-27 | Roche Innovation Center Copenhagen A/S | Short Interfering RNA (siRNA) Analogues |
| CN101273051B (zh) | 2003-04-13 | 2012-04-18 | 安龙制药公司 | 聚合寡核苷酸前体药物 |
| MXPA05012939A (es) * | 2003-05-30 | 2006-05-17 | Astrazeneca Uk Ltd | Procedimiento. |
| PT1733056E (pt) | 2004-03-31 | 2013-08-29 | Gen Hospital Corp | Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CA3044969A1 (en) | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| AU2007296055A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
| EP2090127A2 (en) | 2006-10-30 | 2009-08-19 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| US20100112687A1 (en) | 2007-03-02 | 2010-05-06 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| WO2008112903A2 (en) * | 2007-03-13 | 2008-09-18 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes |
| NZ581201A (en) | 2007-05-11 | 2012-05-25 | Enzon Pharmaceuticals Inc | Rna antagonist compounds for the modulation of her3 |
-
2008
- 2008-05-09 NZ NZ581201A patent/NZ581201A/en not_active IP Right Cessation
- 2008-05-09 AU AU2008250033A patent/AU2008250033A1/en not_active Abandoned
- 2008-05-09 EP EP08759503A patent/EP2155877A2/en not_active Withdrawn
- 2008-05-09 CA CA002686908A patent/CA2686908A1/en not_active Abandoned
- 2008-05-09 TW TW097117351A patent/TW200908987A/zh unknown
- 2008-05-09 US US12/118,271 patent/US8268793B2/en not_active Expired - Fee Related
- 2008-05-09 MX MX2009012271A patent/MX2009012271A/es active IP Right Grant
- 2008-05-09 JP JP2010506953A patent/JP2010526797A/ja active Pending
- 2008-05-09 WO PCT/EP2008/055779 patent/WO2008138904A2/en not_active Ceased
- 2008-05-09 CN CN200880024089A patent/CN101849007A/zh active Pending
- 2008-05-09 KR KR1020097025807A patent/KR20100024410A/ko not_active Ceased
- 2008-05-09 EA EA200971049A patent/EA200971049A1/ru unknown
- 2008-05-09 BR BRPI0811156A patent/BRPI0811156A2/pt not_active IP Right Cessation
-
2009
- 2009-11-10 IL IL202038A patent/IL202038A0/en unknown
-
2012
- 2012-06-22 US US13/531,307 patent/US20120295955A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100024410A (ko) | 2010-03-05 |
| US20120295955A1 (en) | 2012-11-22 |
| CA2686908A1 (en) | 2008-11-20 |
| IL202038A0 (en) | 2011-08-01 |
| EA200971049A1 (ru) | 2010-04-30 |
| WO2008138904A2 (en) | 2008-11-20 |
| US8268793B2 (en) | 2012-09-18 |
| TW200908987A (en) | 2009-03-01 |
| US20080318894A1 (en) | 2008-12-25 |
| BRPI0811156A2 (pt) | 2019-09-24 |
| EP2155877A2 (en) | 2010-02-24 |
| JP2010526797A (ja) | 2010-08-05 |
| NZ581201A (en) | 2012-05-25 |
| AU2008250033A1 (en) | 2008-11-20 |
| CN101849007A (zh) | 2010-09-29 |
| WO2008138904A3 (en) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012271A (es) | Compuestos antagonistas de acido ribonucleico para la modulacion de her3. | |
| MX2009011878A (es) | Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina. | |
| EA201101650A1 (ru) | Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний | |
| MX2010006039A (es) | Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica. | |
| MX2009003729A (es) | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. | |
| IL243812A0 (en) | Compounds of diarylhydantoin | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| WO2010048026A3 (en) | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment | |
| MX2013004086A (es) | Metodos para inhibir proliferacion celular en cancers accionados por egfr. | |
| WO2008144507A3 (en) | Spirooxindole inhibitors of aurora kinase | |
| WO2007127010A3 (en) | Diarylthiohydantoin compounds | |
| MX2010009743A (es) | Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami | |
| GEP20125647B (en) | Kinesin inhibitors as cancer therapeutics | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| MX355325B (es) | Quinazolincarboxamida azetidinas. | |
| MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| WO2009030224A3 (de) | Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen | |
| NZ592326A (en) | Erbb-3 (her3)-selective combination therapy | |
| TW200724537A (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
| WO2008060945A3 (en) | Diagnosis and treatment of breast cancer | |
| UA100545C2 (ru) | Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт | |
| WO2010007522A8 (en) | Rna antagonists targeting gli2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |